Clinical Trial Update: The Use of Icosapent Ethyl on Vascular Progenitor Cells in Individuals With Elevated Cardiovascular Risk [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial evaluated the effect of icosapent ethyl on vascular progenitor cells in individuals with elevated cardiovascular risk.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cardiovascular Diseases
• Cardiovascular Risk Factors
• Hypertriglyceridemia
• Type 2 Diabetes Mellitus

Drugs mentioned

• ICOSAPENT ETHYL (icosapent ethyl)

Snippet

Sponsor: Canadian Medical and Surgical Knowledge Translation Research Group | Conditions: Cardiovascular Diseases, Cardiovascular Risk Factor | Phase 4 | Status: COMPLETED